AbFero 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
SP-420 / AbFero
2022-002395-36: A study of open administration of a drug, which removes iron from the body of patients with transfusion-dependent β-thalassemia, aiming to find the most appropriate dose through use of different dose levels in different patients

Ongoing
2
90
Europe
SP-420, SP-420, Capsule, hard
Pharmacosmos A/S, Pharmacosmos A/S
Transfusion-dependent β-thalassemia, Beta-thalassemia is a rare disease that is inherited and leads to a reduced production of hemoglobin (anemia)., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT05693909: A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia

Recruiting
2
90
Europe
SP-420
Pharmacosmos A/S, ICON plc
Beta Thalassemia Major Anemia
07/24
12/24
NCT04741542: Safety of SP-420 in the Treatment of Transfusional Iron Overload

Suspended
1
28
US
SP-420, (4S)-4,5-dihydro-2-[2-hydroxy-4-[2-(2-methoxyethoxy)ethoxy]phenyl]-4-methyl-4-thiazolecarboxylic acid
The University of Texas Health Science Center at San Antonio, Abfero Pharmaceuticals, Inc
Iron Overload
12/24
08/25

Download Options